- Molecular NameChlorpropamide
- SynonymChlorporpamide
- Weight276.744
- Drugbank_IDDB00672
- ACS_NO94-20-2
- Show 3D model
- LogP (experiment)2.27
- LogP (predicted, AB/LogP v2.0)2.16
- pka5.0
- LogD (pH=7, predicted)-0.23
- Solubility (experiment)2.2 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.1
- LogSw (predicted, AB/LogsW2.0)0.15
- Sw (mg/ml) (predicted, ACD/Labs)0.32
- No.of HBond Donors2
- No.of HBond Acceptors5
- No.of Rotatable Bonds4
- TPSA83.65
- StatusFDA approved
- AdministrationN/A
- PharmacologyA drug in the sulphonylurea class used to treat type 2 diabetes mellitus.
- Absorption_value95.0
- Absorption (description)Rapidly and completely absorbed after oral administration.
- Caco_2N/A
- Bioavailability95.0
- Protein binding77.5
- Volume of distribution (VD)0.1 to 0.3 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe main metabolic reactions are hydroxylation at the 2- and 3-positions of the propyl substituent in the side-chain, N-dealkylation and hydrolysis to form the sulfonamide metabolite.
- Half life35 h
- ExcretionAbout 80% of a single oral dose is excreted in the urine in 7 days. During chronic therapy, up to 100% of a dose is excreted in the urine in 24 h, with about 18% of the dose as unchanged drug, 2% as 4-chlorobenzenesulfonamide, 20% as 4-chlorobenzenesulfonylurea, 55% as 2-hydroxychlorpropamide, and 2% as 3-hydroxychlorpropamide.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityProlonged hypoglycaemic coma has been reported after overdosage but fatalities are comparatively rare, although some instances of fatal blood dyscrasias have been reported. Peak plasma concentrations of 200 to 750 mg/L have been observed in comatose subjects.
- LD50 (rat)N/A
- LD50 (mouse)N/A